Compare RSVR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSVR | ALT |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.7M | 573.8M |
| IPO Year | 2020 | 2005 |
| Metric | RSVR | ALT |
|---|---|---|
| Price | $9.89 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.50 | ★ $17.67 |
| AVG Volume (30 Days) | 45.6K | ★ 5.0M |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.33 | ★ 25.37 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $175,664,491.00 | $41,000.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | $75.15 | ★ N/A |
| Revenue Growth | 10.69 | ★ 105.00 |
| 52 Week Low | $7.07 | $2.56 |
| 52 Week High | $13.39 | $6.44 |
| Indicator | RSVR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 56.90 |
| Support Level | $9.85 | $2.80 |
| Resistance Level | $10.34 | $3.32 |
| Average True Range (ATR) | 0.34 | 0.14 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 42.58 | 72.50 |
Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.